Bio-Techne Corp
Nasdaq-listed company. Follow earnings, filings, products, capital and the competitive forces moving the company.
What’s moving Bio-Techne Corp now
Current reporting with the operating signal separated from the noise.
Form 4 Bio-Techne Corp For: 31 July By Investing.com
The story matters when it changes Bio-Techne Corp’s customers, execution, competitive position or capital requirements.
Watch next: confirmation in a company filing, official release or regulator record.Bio-Techne Corp (TECH) CFO exercises 62,068 options, 51,024 shares withheld
Investors are testing whether Bio-Techne Corp’s operating performance supports its strategy and valuation.
Watch next: the filing, cash flow, guidance and capital-expenditure plan.Bio-Techne Corp (TECH) Valuation: PE, PB & Fair Value Analysis
The development tests whether Bio-Techne Corp can turn product investment into adoption, revenue and durable advantage.
Watch next: confirmation in a company filing, official release or regulator record.BIO-TECHNE Corp (NASDAQ: TECH) CEO exercises 35,000 options, 28,686 shares withheld
Investors are testing whether Bio-Techne Corp’s operating performance supports its strategy and valuation.
Watch next: the filing, cash flow, guidance and capital-expenditure plan.TECH|Bio-Techne Corp|Price:72.090|Chg%:+0.060
The story matters when it changes Bio-Techne Corp’s customers, execution, competitive position or capital requirements.
Watch next: confirmation in a company filing, official release or regulator record.Bio-Techne Corp (TECH) Financial Health: Profitability & Balance Sheet Analysis
Investors are testing whether Bio-Techne Corp’s operating performance supports its strategy and valuation.
Watch next: the filing, cash flow, guidance and capital-expenditure plan.Bio-Techne Corp (TECH) Q2 2026 Earnings: EPS Misses Estimates as Revenue Data Remains Unreported - Dividend Earnings Report
Investors are testing whether Bio-Techne Corp’s operating performance supports its strategy and valuation.
Watch next: the filing, cash flow, guidance and capital-expenditure plan.Bio-Techne Corp (TECH) Holds Steady Near Mid-Range as Life Sciences Sector Sees Mixed Signals - Volume Breadth
The story matters when it changes Bio-Techne Corp’s customers, execution, competitive position or capital requirements.
Watch next: confirmation in a company filing, official release or regulator record.Bio-Techne Corp (TECH) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution
Investors are testing whether Bio-Techne Corp’s operating performance supports its strategy and valuation.
Watch next: the filing, cash flow, guidance and capital-expenditure plan.Bio-Techne Corp. stock outperforms competitors on strong trading day
Investors are testing whether Bio-Techne Corp’s operating performance supports its strategy and valuation.
Watch next: the filing, cash flow, guidance and capital-expenditure plan.Bio-Techne Corporation (TECH) Presents at TD Cowen 46th Annual Health Care Conference Transcript
The story matters when it changes Bio-Techne Corp’s customers, execution, competitive position or capital requirements.
Watch next: confirmation in a company filing, official release or regulator record.Bio-Techne Corporation (TECH) Slid on Weakness in Research Spending
The story matters when it changes Bio-Techne Corp’s customers, execution, competitive position or capital requirements.
Watch next: confirmation in a company filing, official release or regulator record.Latest TECH filings.
Investor-relevant reports are shown first, followed by the company’s other recent official submissions.
Bio-Techne Corp, quarter by quarter.
Results, guidance and earnings coverage are grouped only when the source headline identifies the reporting period.
First quarter
No verified period-specific item in the current feed.
SEARCH Q1 COVERAGE →